Son y\u0131llarda onkoloji alan\u0131nda sa\u011flanan \u00f6nemli ilerlemeler, kanser tedavisinde yeni ufuklar a\u00e7\u0131yor. University of Texas MD Anderson Cancer Center taraf\u0131ndan y\u00fcr\u00fct\u00fclen kapsaml\u0131 ara\u015ft\u0131rmalar, pankreas kanserinden l\u00f6semiye, akci\u011fer kanserinden beyin t\u00fcm\u00f6rlerine kadar farkl\u0131 kanser t\u00fcrlerinde tedavi yakla\u015f\u0131mlar\u0131n\u0131 k\u00f6kl\u00fc \u015fekilde de\u011fi\u015ftirme potansiyeline sahip. Bu \u00e7al\u0131\u015fmalar, klinik uygulamalar ile molek\u00fcler bilimlerin integrasyonunun, kanser biyolojisi ve hasta bak\u0131m\u0131nda nas\u0131l devrim yaratabilece\u011fini a\u00e7\u0131k\u00e7a ortaya koyuyor.<\/p>\n
Pankreas kanseri, genellikle tan\u0131dan k\u0131sa s\u00fcre sonra metastaz yapmas\u0131 nedeniyle zorlu bir malignite olarak bilinmektedir ve be\u015f y\u0131ll\u0131k sa\u011fkal\u0131m oran\u0131 sadece %12 civar\u0131ndad\u0131r. Dr. Linghua Wang ve Dr. Anirban Maitra liderli\u011finde yap\u0131lan \u00e7al\u0131\u015fmada; 13 hastadan al\u0131nan 55 t\u00fcm\u00f6r \u00f6rne\u011fi, y\u00fcksek \u00e7\u00f6z\u00fcn\u00fcrl\u00fckl\u00fc mekan alan\u0131 haritalama teknikleriyle detayl\u0131 incelendi. Bu sayede kanser h\u00fccrelerinin pankreastan uzak organlara ge\u00e7i\u015fi s\u0131ras\u0131nda ya\u015fanan klonal evrim ve t\u00fcm\u00f6r mikro\u00e7evresi dinamikleri ayr\u0131nt\u0131l\u0131 \u015fekilde analiz edildi. \u00c7al\u0131\u015fmada, iki ayr\u0131 epitelyal fenotip ve bunlara \u00f6zg\u00fc transcriptomik profiller saptand\u0131. Bu fenotiplerin her biri farkl\u0131 prognoza sahip olmas\u0131, pankreas kanseri biyobelirte\u00e7 belirleme ve hedefe y\u00f6nelik tedavi geli\u015ftirme s\u00fcre\u00e7lerinde h\u00fccresel heterojenitenin ve mikro\u00e7evresel fakt\u00f6rlerin dikkate al\u0131nmas\u0131n\u0131n \u00f6nemine vurgu yapt\u0131.<\/p>\n
Akci\u011fer kanseri, \u00e7o\u011fu zaman ileri evrelerde tan\u0131 ald\u0131\u011f\u0131 i\u00e7in erken d\u00f6nemdeki ba\u011f\u0131\u015f\u0131kl\u0131k de\u011fi\u015fimlerinin anla\u015f\u0131lmas\u0131, hastal\u0131k m\u00fcdahalesi i\u00e7in kritik. Dr. Bo Zhu ve Dr. Jia Wu\u2019nun \u00f6nderli\u011findeki ekip, 114 akci\u011fer doku \u00f6rne\u011fini g\u00f6r\u00fcnt\u00fc k\u00fctle sitometrisi ile analiz ederek, hastal\u0131k ilerlerken edinilmi\u015f ba\u011f\u0131\u015f\u0131kl\u0131ktan adaptif ba\u011f\u0131\u015f\u0131kl\u0131\u011fa ge\u00e7i\u015f s\u00fcre\u00e7lerini inceledi. \u00c7al\u0131\u015fma, ba\u011f\u0131\u015f\u0131kl\u0131k kontrol noktas\u0131 resept\u00f6r\u00fc TIM-3\u2019\u00fcn precancer\u00f6z evrelerde y\u00fcksek seviyelerde, t\u00fcm\u00f6r\u00fcn invazif hale ge\u00e7i\u015finde ise azald\u0131\u011f\u0131n\u0131 g\u00f6sterdi. TIM-3 engellemenin erken d\u00f6nemde t\u00fcm\u00f6r b\u00fcy\u00fcmesini \u00f6nemli \u00f6l\u00e7\u00fcde yava\u015flatt\u0131\u011f\u0131 deneysel verilerle kan\u0131tlanarak, erken immunoterapi hedefi olarak b\u00fcy\u00fck potansiyele sahip oldu\u011fu ortaya kondu.<\/p>\n
Mantle h\u00fccre lenfomas\u0131 (MCL), standart tedavilere genellikle diren\u00e7li, agresif B h\u00fccreli bir lenfomad\u0131r. Dr. Michael Wang liderli\u011finde y\u00fcr\u00fct\u00fclen ECHO Faz III klinik \u00e7al\u0131\u015fmas\u0131, akalabrutinib isimli se\u00e7ici ikinci nesil Bruton tirozin kinaz inhibit\u00f6r\u00fcn\u00fcn standart tedaviye eklenmesini ara\u015ft\u0131rd\u0131. 598 hastan\u0131n dahil edildi\u011fi bu geni\u015f \u00f6l\u00e7ekli \u00e7al\u0131\u015fmada, median progresyonsuz sa\u011fkal\u0131m akalabrutinib grubunda 66.4 aya kadar uzarken, plasebo kolunda 49.6 ay olarak kaydedildi. G\u00fcvenlik profili ve etkinlik sonu\u00e7lar\u0131 FDA\u2019n\u0131n bu kombinasyonu MCL\u2019de yeni birinci basamak standart tedavi olarak onaylamas\u0131na zemin haz\u0131rlad\u0131, \u00f6zellikle yeni tan\u0131 alan ya\u015fl\u0131 hastalar i\u00e7in \u00f6nemli bir geli\u015fme olarak de\u011ferlendirildi.<\/p>\n
Akut miyeloid l\u00f6semi (AML), kemoterapiye diren\u00e7 g\u00f6stermesinin temel nedeni olan kemik ili\u011finde quiescent (uyku) durumda bulunan l\u00f6semi k\u00f6k\/progenit\u00f6r h\u00fccrelerin tedavisi b\u00fcy\u00fck zorluklar yaratmaktad\u0131r. Dr. Michael Andreeff ve Dr. Yuki Nishida liderli\u011findeki \u00e7al\u0131\u015fmada, valemetostat adl\u0131 EZH1 ve EZH2 epigenetik reg\u00fclat\u00f6rlerini hedefleyen \u00e7ift inhibit\u00f6r ile LSPC\u2019lerin uyar\u0131lmas\u0131 hedeflendi. Bu yakla\u015f\u0131m, do\u011frudan sitotoksik etki g\u00f6stermeyip h\u00fccrelerin uyku halinden \u00e7\u0131kmas\u0131n\u0131 sa\u011flayarak klasik kemoterapi ila\u00e7lar\u0131n\u0131n etkinli\u011fini art\u0131rd\u0131. Sa\u011fl\u0131kl\u0131 hematopoetik k\u00f6k h\u00fccreler etkilenmeden, hastalarda artan l\u00f6semi h\u00fccresi yok edilmesi ve iyile\u015fen hayatta kal\u0131m oranlar\u0131, AML tedavisinde yeni diren\u00e7 k\u0131r\u0131c\u0131 stratejiler sunuyor.<\/p>\n
Glioblastoma multiforme, primer beyin t\u00fcm\u00f6rleri i\u00e7inde en yayg\u0131n ve en \u00f6l\u00fcmc\u00fcl t\u00fcrd\u00fcr. Ba\u011f\u0131\u015f\u0131kl\u0131k kontrol noktas\u0131 hedefli tedavilere diren\u00e7 g\u00f6stermesiyle zorluk arz etmektedir. Dr. Shiao-Pei Weathers\u2019\u0131n y\u00fcr\u00fctt\u00fc\u011f\u00fc Faz I\/II klinik ara\u015ft\u0131rmada, atezolizumab tedavisi, temozolomid kemoterapisi ile radyoterapi kombinasyonu yeni tan\u0131 konmu\u015f glioblastoma hastalar\u0131nda denendi. Genel sa\u011fkal\u0131m oranlar\u0131 mevcut standartlarla benzer olmakla birlikte, imm\u00fcn a\u00e7\u0131s\u0131ndan zengin t\u00fcm\u00f6r mikro\u00e7evresi olan hastalarda daha iyi sonu\u00e7lar g\u00f6zlendi. \u00d6zellikle mezankimal alt tipteki t\u00fcm\u00f6rler belirgin \u015fekilde ba\u011f\u0131\u015f\u0131kl\u0131k aktivitesi g\u00f6sterdi. Ayr\u0131ca ba\u011f\u0131rsak mikrobiyotas\u0131ndaki spesifik profil ile imm\u00fcn yan\u0131t aras\u0131ndaki pozitif ili\u015fki, beyin-tum\u00f6r ve ba\u011f\u0131rsak ekseni \u00fczerinde yeni \u00e7al\u0131\u015fmalar yap\u0131lmas\u0131n\u0131n gereklili\u011fini ortaya koydu.<\/p>\n
Uzun vadeli kanser ya\u015fant\u0131s\u0131 ve ya\u015fam kalitesinin art\u0131r\u0131lmas\u0131na y\u00f6nelik yap\u0131lan \u00f6nemli psikososyal \u00e7al\u0131\u015fmalardan biri, ya\u015fl\u0131 meme kanseri hastalar\u0131nda kronik a\u011fr\u0131 y\u00f6netiminde \u00f6z savunuculu\u011fun etkisini ara\u015ft\u0131rd\u0131. Dr. Karen E. Alsbrook\u2019un y\u00fcr\u00fctt\u00fc\u011f\u00fc 65 ya\u015f ve \u00fczeri hasta grubunda, hastalar\u0131n sa\u011fl\u0131k personeliyle ileti\u015fimi, a\u011fr\u0131 alg\u0131lar\u0131 ve opioid kullan\u0131m\u0131 konusundaki damgalanma \u00f6l\u00e7\u00fcld\u00fc. Aktif \u00f6z savunuculuk g\u00f6steren hastalarda daha etkin ileti\u015fim ve daha d\u00fc\u015f\u00fck a\u011fr\u0131 seviyeleri raporland\u0131. Bu sonu\u00e7lar, hasta merkezli bak\u0131m\u0131n kanser sonras\u0131 a\u011fr\u0131 y\u00f6netiminde \u00f6nemli oldu\u011funu ve hem\u015fire \u00f6nc\u00fcl\u00fc\u011f\u00fcnde e\u011fitici m\u00fcdahalelerin desteklenmesi gerekti\u011fini vurgulad\u0131.<\/p>\n
MD Anderson Cancer Center\u2019\u0131n bilimsel \u00e7abalar\u0131, \u00f6nemli akademik ve profesyonel \u00f6d\u00fcllerle de ta\u00e7land\u0131r\u0131ld\u0131. Anirban Maitra ve Scott Kopetz gibi alt\u0131 profes\u00f6r, t\u0131pta vizyoner ara\u015ft\u0131rmalar\u0131yla tan\u0131nan American Association of Physicians \u00fcyeli\u011fine kabul edildi. Ken Chen, kanser genomiklerinde kritik bir rol oynayan hesaplamal\u0131 biyoloji ve biyoinformatik alan\u0131ndaki katk\u0131lar\u0131yla Amerikan Medikal ve Biyolojik M\u00fchendisli\u011fi Enstit\u00fcs\u00fc\u2019ne se\u00e7ildi. Meme kanseri ara\u015ft\u0131rmalar\u0131 alan\u0131nda liderlik yapan Gabriel Hortobagyi ise European Society of Medical Oncology Breast Cancer Award\u2019\u0131n\u0131 ald\u0131. Ayr\u0131ca pediatrik ve eri\u015fkin l\u00f6semi tedavilerine \u00f6nc\u00fcl\u00fck eden Richard Gorlick ile Michael Andreeff, Giants of Cancer Care 2025 s\u0131n\u0131f\u0131na se\u00e7ilerek global etki alanlar\u0131n\u0131 geni\u015fletti.<\/p>\n
Bu d\u00f6n\u00fcm noktas\u0131 niteli\u011findeki \u00e7al\u0131\u015fmalar, spatial transcriptomics ve y\u00fcksek boyutlu g\u00f6r\u00fcnt\u00fcleme gibi modern metodolojilerin yan\u0131 s\u0131ra hedefe y\u00f6nelik molek\u00fcler inhibit\u00f6rlerin klinik uygulamalarla birle\u015fti\u011fi bir d\u00f6nemi simgeliyor. T\u00fcm\u00f6r biyolojisi, ba\u011f\u0131\u015f\u0131kl\u0131k dinamikleri ve hasta merkezli yakla\u015f\u0131mlar\u0131n birlikteli\u011fi, MD Anderson\u2019\u0131n \u00f6nc\u00fcl\u00fc\u011f\u00fcnde kanser bak\u0131m\u0131nda yeni bir \u00e7a\u011f\u0131 ba\u015flat\u0131yor. Bu entegre stratejiler, hastalar\u0131n ya\u015fam kalitesini y\u00fckseltirken, tedavi ba\u015far\u0131s\u0131n\u0131 da \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131rma potansiyeline sahip.<\/p>\n
Kanser biyolojisinde h\u00fccresel heterojenitenin anla\u015f\u0131lmas\u0131 ve t\u00fcm\u00f6r mikro\u00e7evresinin rol\u00fcne odaklanan kapsaml\u0131 atlas \u00e7al\u0131\u015fmalar\u0131, \u00f6zellikle pankreas kanseri gibi zorlay\u0131c\u0131 t\u00fcm\u00f6r tiplerinde biyobelirte\u00e7 geli\u015ftirme yolunda temel olu\u015fturuyor. \u00c7al\u0131\u015fmalar, bu heterojenite g\u00f6z ard\u0131 edildi\u011finde tedavi diren\u00e7lerinin \u00f6n\u00fcne ge\u00e7menin m\u00fcmk\u00fcn olmayaca\u011f\u0131n\u0131 g\u00f6steriyor. B\u00f6ylece, ki\u015fiye \u00f6zel tedavi yakla\u015f\u0131mlar\u0131n\u0131n geli\u015ftirilmesi i\u00e7in molek\u00fcler ve doku d\u00fczeyinde detayl\u0131 haritalama anlay\u0131\u015f\u0131 kritik \u00f6nem kazan\u0131yor.<\/p>\n
Ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin kanserle etkile\u015fiminin zaman i\u00e7inde nas\u0131l evrildi\u011finin ortaya konmas\u0131, erken evre akci\u011fer kanseri tedavilerinde yeni immunoterapi hedefleri sunuyor. TIM-3 gibi ba\u011f\u0131\u015f\u0131kl\u0131k kontrol noktalar\u0131na y\u00f6nelik erken m\u00fcdahaleler, hastan\u0131n hastal\u0131k invazif hale gelmeden \u00f6nce tedavi \u015fans\u0131n\u0131 art\u0131r\u0131yor. Bu da imm\u00fcnoterapilerin sadece ileri evrelerde de\u011fil, precancer\u00f6z lezyonlarda da etkin \u015fekilde kullan\u0131labilece\u011finin i\u015fareti say\u0131l\u0131yor.<\/p>\n
L\u00f6semi tedavisinde yeni nesil Bruton tirozin kinaz inhibit\u00f6rlerinin devreye girmesi ve kemoterapi diren\u00e7li h\u00fccrelerin uyand\u0131r\u0131lmas\u0131 y\u00f6ntemi, hematolojik malignitelerde tedavi paradigmas\u0131n\u0131 de\u011fi\u015ftiriyor. B\u00f6ylelikle, kemik ili\u011fi mikro\u00e7evresindeki sessiz h\u00fccrelerin uyar\u0131lmas\u0131 sa\u011flanarak, standart tedavilerin etkinli\u011fi art\u0131r\u0131l\u0131yor. Bu stratejiler, gelece\u011fin hematoloji kliniklerinde s\u0131k\u00e7a kullan\u0131lacak y\u00f6ntemler aras\u0131nda yerini al\u0131yor.<\/p>\n
Ayn\u0131 zamanda, beyin t\u00fcm\u00f6rlerinin alt tiplerine g\u00f6re imm\u00fcn yan\u0131t farkl\u0131l\u0131klar\u0131 ve ba\u011f\u0131rsak mikrobiyotas\u0131n\u0131n etkisinin ke\u015ffi, ki\u015fiselle\u015ftirilmi\u015f imm\u00fcnoterapilerin tasar\u0131m\u0131nda yeni bak\u0131\u015f a\u00e7\u0131lar\u0131 kazand\u0131r\u0131yor. Ba\u011f\u0131rsak ve beyin aras\u0131ndaki eksenin, kanser imm\u00fcnoterapisine etkisi konusunda yap\u0131lan bu \u00f6nc\u00fc \u00e7al\u0131\u015fmalar, multidisipliner yakla\u015f\u0131mlar\u0131n \u00f6nemini bir kez daha ortaya koydu.<\/p>\n
Son olarak, kanser tedavisi ve sonras\u0131ndaki bak\u0131m s\u00fcre\u00e7lerinde psikososyal fakt\u00f6rlerin g\u00f6z ard\u0131 edilmemesi gerekti\u011fi vurgulan\u0131yor. \u00d6z savunuculu\u011fun hasta ya\u015fam kalitesi \u00fczerinde olumlu etkileri g\u00f6r\u00fcl\u00fcrken; sa\u011fl\u0131k sistemlerinde hasta e\u011fitimi ve destek programlar\u0131 g\u00fc\u00e7lendirilerek a\u011fr\u0131 y\u00f6netimi ve tedavi uyumu art\u0131r\u0131labilir. Bu, modern onkolojide b\u00fct\u00fcnc\u00fcl bak\u0131m yakla\u015f\u0131m\u0131n\u0131n tart\u0131\u015f\u0131lmaz gereklili\u011fini kan\u0131tl\u0131yor.<\/p>\n
T\u00fcm bu geli\u015fmeler, MD Anderson Cancer Center\u2019\u0131n kanser ara\u015ft\u0131rmalar\u0131 alan\u0131nda ne denli ileri bir seviyeye ula\u015ft\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Klinik ve temel bilim ara\u015ft\u0131rmalar\u0131n\u0131 uyum i\u00e7inde y\u00fcr\u00fcterek \u00fcretilen bu veriler, gelece\u011fin kanser terapileri i\u00e7in sa\u011flam bir altyap\u0131 olu\u015fturuyor. Hastalar\u0131n hem ya\u015fam s\u00fcresi hem de ya\u015fam kalitesini art\u0131racak bu kapsaml\u0131 ve yenilik\u00e7i yakla\u015f\u0131mlar, onkoloji sahas\u0131nda umut verici bir d\u00f6nemin kap\u0131lar\u0131n\u0131 aral\u0131yor.<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Web References<\/strong>: Anahtar Kelimeler<\/strong>: Son y\u0131llarda onkoloji alan\u0131nda sa\u011flanan \u00f6nemli ilerlemeler, kanser tedavisinde yeni ufuklar a\u00e7\u0131yor. University of Texas MD Anderson Cancer Center taraf\u0131ndan y\u00fcr\u00fct\u00fclen kapsaml\u0131 ara\u015ft\u0131rmalar, pankreas kanserinden l\u00f6semiye, akci\u011fer kanserinden beyin t\u00fcm\u00f6rlerine kadar farkl\u0131 kanser t\u00fcrlerinde tedavi yakla\u015f\u0131mlar\u0131n\u0131 k\u00f6kl\u00fc \u015fekilde de\u011fi\u015ftirme potansiyeline sahip. Bu \u00e7al\u0131\u015fmalar, klinik uygulamalar ile molek\u00fcler bilimlerin integrasyonunun, kanser biyolojisi ve hasta bak\u0131m\u0131nda nas\u0131l…<\/p>\n","protected":false},"author":1,"featured_media":5223,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[6453,6455,6451,6452,6454],"tmauthors":[],"class_list":["post-5222","post","type-post","status-publish","format-standard","has-post-thumbnail","category-kanser","tag-akciger-kanserinde-erken-bagisiklik-degisimleri","tag-mantle-hucre-lenfomasi-akalabrutinib-klinik-calismasi","tag-md-anderson-kanser-arastirmalari-2025","tag-pankreas-kanseri-molekuler-biyoloji-calismalari","tag-tim-3-immunoterapi-hedefleri"],"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/05\/MD-Anderson-2025-Mayis-Arastirma-Atilimlari-1746727206.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=5222"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5222\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/5223"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=5222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=5222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=5222"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=5222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nKapsaml\u0131 kanser biyolojisi, tedavi stratejileri ve hasta bak\u0131m\u0131na y\u00f6nelik geli\u015fmeler; pankreas kanseri, akci\u011fer kanseri, mantel h\u00fccre lenfomas\u0131, akut miyeloid l\u00f6semi, glioblastoma ve meme kanseri sa\u011fkal\u0131m sonras\u0131 konular\u0131.<\/p>\n
\nRevolutionizing Oncology: MD Anderson\u2019s Breakthroughs in Cancer Research and Patient Care<\/p>\n
\nhttps:\/\/www.mdanderson.org\/newsroom\/research-highlights.html
\nhttps:\/\/www.mdanderson.org\/newsroom\/research-highlights\/comprehensive-spatial-map-provides-insights-into-pancreatic-cancer-metastases.h00-159775656.html
\nhttps:\/\/www.nature.com\/articles\/s41586-025-08927-x
\nhttps:\/\/www.mdanderson.org\/newsroom\/research-highlights\/mapping-changes-in-lung-precancer-reveals-tim-3-as-potential-intervention-target.h00-159776445.html
\nhttps:\/\/www.cell.com\/cancer-cell\/fulltext\/S1535-6108(25)00162-X
\nhttps:\/\/www.mdanderson.org\/newsroom\/research-highlights\/novel-combination-provides-more-effective-treatment-option-for-mantle-cell-lymphoma.h00-159776445.html
\nhttps:\/\/ascopubs.org\/doi\/pdf\/10.1200\/JCO-25-00690
\nhttps:\/\/www.mdanderson.org\/newsroom\/research-highlights\/activating-leukemia-stem-cells-makes-chemotherapy-more-effective-in-AML.h00-159776445.html
\nhttps:\/\/www.nature.com\/articles\/s41408-025-01266-0
\nhttps:\/\/www.mdanderson.org\/newsroom\/research-highlights\/study-identifies-potential-biomarker-for-treatment-response-in-glioblastoma.h00-159776445.html
\nhttps:\/\/www.nature.com\/articles\/s41467-025-56930-7
\nhttps:\/\/www.mdanderson.org\/newsroom\/research-highlights\/self-advocacy-may-lead-to-less-pain-in-older-breast-cancer-survivors.h00-159776445.html
\nhttps:\/\/www.ons.org\/publications-research\/onf\/52\/3\/associations-among-self-advocacy-patient-centered-communication-pain<\/p>\n
\nKanser ara\u015ft\u0131rmalar\u0131, pankreas kanseri, akci\u011fer kanseri, mantel h\u00fccre lenfomas\u0131, akut miyeloid l\u00f6semi, glioblastoma, meme kanseri, t\u00fcm\u00f6r mikro\u00e7evresi, ba\u011f\u0131\u015f\u0131kl\u0131k kontrol noktas\u0131, spatial transcriptomics, BTK inhibit\u00f6rleri, EZH1\/2 inhibit\u00f6r\u00fc, hasta \u00f6z savunuculu\u011fu, imm\u00fcn biyobelirte\u00e7ler, kanser genomikleri.<\/p>\n","protected":false},"excerpt":{"rendered":"